News
LSB
2.595
+0.19%
0.005
Weekly Report: what happened at LSB last week (1104-1108)?
Weekly Report · 6d ago
LakeShore Biopharma Advances PIKA Rabies Vaccine Approval
TipRanks · 11/07 13:50
LakeShore Biopharma initiates BLA submission to DRAP for PIKA rabies vaccine
TipRanks · 11/07 13:24
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/05 16:34
Weekly Report: what happened at LSB last week (1028-1101)?
Weekly Report · 11/04 11:09
LakeShore Biopharma Announces Leadership Transition
TipRanks · 11/01 20:32
LakeShore Biopharma Achieves Nasdaq Compliance Milestone
TipRanks · 10/29 13:48
Weekly Report: what happened at LSB last week (1021-1025)?
Weekly Report · 10/28 11:02
LakeShore Biopharma Advances with Rabies Vaccine Trial
TipRanks · 10/25 13:00
LakeShore’s YSJA rabies vaccine receives approval for Phase III trial in China
TipRanks · 10/25 12:35
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 10/23 12:07
Weekly Report: what happened at LSB last week (1014-1018)?
Weekly Report · 10/21 10:59
Weekly Report: what happened at LSB last week (1007-1011)?
Weekly Report · 10/14 11:24
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/11 12:07
PepsiCo reports mixed Q3, Roblox slips after short report: Morning Buzz
TipRanks · 10/08 16:01
LakeShore Biopharma Projects Strong Growth in 2025
TipRanks · 10/08 13:27
LakeShore Biopharma provides HY guidance
Seeking Alpha · 10/08 13:14
LakeShore Biopharma still sees FY25 revenue up in double digits year-over-year
TipRanks · 10/08 12:41
Weekly Report: what happened at LSB last week (0930-1004)?
Weekly Report · 10/07 11:15
Weekly Report: what happened at LSB last week (0923-0927)?
Weekly Report · 09/30 11:08
More
Webull provides a variety of real-time LSB stock news. You can receive the latest news about LakeShore Biopharma Co., Ltd through multiple platforms. This information may help you make smarter investment decisions.
About LSB
LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.